Pharma BD Deal Intelligence
CEO Hatanaka: 'We highly value Ocata's R&D capabilities, including its world-leading researchers in cell therapy.' The $8.50/share, ~$379M all-cash deal…
Ocata bought by Astellas of Japan: initial perspectives on end of an era — a reflective take on the acquisition of the pioneering human embryonic stem cell…
The Globe reported only 36% of Ocata shares tendered by the first deadline; dissenting shareholders called the $8.50 offer undervalued versus a prior $12 high…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Astellas acquired Ocata Therapeutics (formerly Advanced Cell Technology) for $8.50/share or approximately $379M cash, establishing presence in ophthalmology and regenerative medicine via hESC-derived RPE cell therapies for Stargardt disease and dry AMD. Closed February 2016. Borderline value but strategically notable for cell therapy pivot.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. (this deal) | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Ganymed Pharmaceuticals | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
| Astellas Pharma Inc. / OSI Pharmaceuticals | 2010 | $4.0B | 33 |
← Browse all deals · How we score deals
More: 2015 deals · Astellas Pharma Inc. deals · Ophthalmology deals